KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Hims & Hers Health (HIMS) Research & Development (2021 - 2025)

Historic Research & Development for Hims & Hers Health (HIMS) over the last 5 years, with Q3 2025 value amounting to $40.6 million.

  • Hims & Hers Health's Research & Development rose 9238.1% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.1 million, marking a year-over-year increase of 9289.96%. This contributed to the annual value of $78.8 million for FY2024, which is 6343.33% up from last year.
  • Hims & Hers Health's Research & Development amounted to $40.6 million in Q3 2025, which was up 9238.1% from $37.8 million recorded in Q2 2025.
  • In the past 5 years, Hims & Hers Health's Research & Development ranged from a high of $40.6 million in Q3 2025 and a low of $5.6 million during Q4 2021
  • Its 5-year average for Research & Development is $16.3 million, with a median of $12.3 million in 2023.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 2779.56% in 2022, then skyrocketed by 10289.48% in 2025.
  • Quarter analysis of 5 years shows Hims & Hers Health's Research & Development stood at $5.6 million in 2021, then surged by 49.16% to $8.3 million in 2022, then soared by 61.29% to $13.4 million in 2023, then surged by 77.17% to $23.7 million in 2024, then surged by 70.86% to $40.6 million in 2025.
  • Its Research & Development was $40.6 million in Q3 2025, compared to $37.8 million in Q2 2025 and $29.9 million in Q1 2025.